Acorda Therapeutics (ACORQ) Stock Price, News & Analysis

Company Overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Key Stats

• Today's Range: $0.01 to $0.01
• 50-Day Range: $0.01 to $0.06
• 52-Week Range: $0.01 to $18.00
• Volume: N/A
• Average Volume: 67,585 shs
• Market Capitalization: $12,420.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ACORQ
• CIK: 1008848
• Web: www.acorda.com
• Phone: 914-347-4300
• Fax: 914-347-4560
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($212.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-252,850,000.00
• Net Margins: -227.75%
• Pretax Margin: -263.21%
• Return on Equity: -2,206.93%
• Return on Assets: -114.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $117.63 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($127.17) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,242,000
• Free Float: 1,210,000
• Market Cap: $12,420.00
• Optionable: N/A
• Beta: 1.67